Sood AK - Search Results

1

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Merritt WM, et al. Among authors: sood ak. Cancer Biol Ther. 2006 Oct;5(10):1357-60. doi: 10.4161/cbt.5.10.3225. Epub 2006 Oct 31. Cancer Biol Ther. 2006. PMID: 16969087

2

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE. Shahin MS, et al. Among authors: sood ak. Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z. Cancer. 2000. PMID: 11064359

3

Molecular determinants of ovarian cancer plasticity.

Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ. Sood AK, et al. Am J Pathol. 2001 Apr;158(4):1279-88. doi: 10.1016/S0002-9440(10)64079-5. Am J Pathol. 2001. PMID: 11290546 Free PMC article.

4

p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.

Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. Buller RE, et al. Among authors: sood ak. Am J Obstet Gynecol. 2001 Apr;184(5):891-902; discussion 902-3. doi: 10.1067/mob.2001.113856. Am J Obstet Gynecol. 2001. PMID: 11303196

5

The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. Buller RE, et al. Among authors: sood ak. Clin Cancer Res. 2001 Apr;7(4):831-8. Clin Cancer Res. 2001. PMID: 11309330

6

The embryonic-like properties of aggressive human tumor cells.

Sood AK, Fletcher MS, Hendrix MJ. Sood AK, et al. J Soc Gynecol Investig. 2002 Jan-Feb;9(1):2-9. doi: 10.1016/s1071-5576(01)00147-2. J Soc Gynecol Investig. 2002. PMID: 11839501 Review.

7

Ovarian cancer p53 mutation is associated with tumor microvessel density.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Goodheart MJ, et al. Among authors: sood ak. Gynecol Oncol. 2002 Jul;86(1):85-90. doi: 10.1006/gyno.2002.6730. Gynecol Oncol. 2002. PMID: 12079305

8

The paradoxical expression of maspin in ovarian carcinoma.

Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. Sood AK, et al. Clin Cancer Res. 2002 Sep;8(9):2924-32. Clin Cancer Res. 2002. PMID: 12231537

9

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.

Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. Sood AK, et al. Cancer Biol Ther. 2002 Sep-Oct;1(5):511-7. doi: 10.4161/cbt.1.5.167. Cancer Biol Ther. 2002. PMID: 12496479

10

The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. Sood AK, et al. Cancer Biol Ther. 2002 Nov-Dec;1(6):661-4. doi: 10.4161/cbt.316. Cancer Biol Ther. 2002. PMID: 12642690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,140 results

Search Page